• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Eye Infections - Pipeline Review, H2 2012 Product Image

Eye Infections - Pipeline Review, H2 2012

  • ID: 2366410
  • December 2012
  • 76 Pages
  • Global Markets Direct

FEATURED COMPANIES

  • Altacor Ltd.
  • Foamix Ltd.
  • LABORATOIRES THEA
  • Lux Biosciences, Inc.
  • NanoViricides, Inc.
  • SIFI Pharma
  • MORE

Eye Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Eye Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Eye Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eye Infections. Eye Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Eye Infections.
- A review of the Eye Infections products under development by companies and universities/research institutes based on information derived from company READ MORE >

FEATURED COMPANIES

  • Altacor Ltd.
  • Foamix Ltd.
  • LABORATOIRES THEA
  • Lux Biosciences, Inc.
  • NanoViricides, Inc.
  • SIFI Pharma
  • MORE

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Eye Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Eye Infections 9
Eye Infections Therapeutics under Development by Companies 11
Eye Infections Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Eye Infections Therapeutics – Products under Development by Companies 18
Eye Infections Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Eye Infections Therapeutics Development 21
Bausch & Lomb Incorporated 21
Lux Biosciences, Inc. 22
InSite Vision Incorporated 23
NanoViricides, Inc. 24
Peregrine Pharmaceuticals, Inc. 25
RegeneRx Biopharmaceuticals, Inc. 26
Foamix Ltd. 27
LABORATOIRES THEA 28
Redox Pharmaceutical Corporation 29
Sirnaomics, Inc. 30
SIFI Pharma 31
Altacor Ltd. 32
Eye Infections – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 40
AzaSite Plus - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
azithromycin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
DexaSite - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RGN-259 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
doxorubicin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SF-111 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SF-101 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SF-105 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
IL-1Ra - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
EKCCide-I - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
T-Pred - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
tetracycline - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LX-214 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
azithromycin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LX-212 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HO/05/09 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
moxifloxacin hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Riboflavin + Ultraviolet Light A - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
hCAP-18/LL-37 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
STP-601 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PGN-632 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Eye Infections Therapeutics – Drug Profile Updates 64
Eye Infections Therapeutics – Discontinued Products 70
Eye Infections Therapeutics - Dormant Products 71
Eye Infections – Product Development Milestones 73
Featured News & Press Releases 73
May 10, 2012: Researchers Present Preclinical Data Of Peregrine Pharma's PGN632 At ARVO 2012 73
Oct 18, 2010: Garamycin Ophthalmic Ointment Now Available from Fera Pharmaceuticals 73
Oct 18, 2010: Garamycin Ophthalmic Ointment Now Available from Fera Pharmaceuticals 73
Oct 18, 2010: Garamycin Ophthalmic Ointment Now Available from Fera Pharmaceuticals 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables
Number of Products Under Development for Eye Infections, H2 2012 9
Products under Development for Eye Infections – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Development by Companies, H2 2012 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2012 20
Bausch & Lomb Incorporated, H2 2012 21
Lux Biosciences, Inc., H2 2012 22
InSite Vision Incorporated, H2 2012 23
NanoViricides, Inc., H2 2012 24
Peregrine Pharmaceuticals, Inc., H2 2012 25
RegeneRx Biopharmaceuticals, Inc., H2 2012 26
Foamix Ltd., H2 2012 27
LABORATOIRES THEA, H2 2012 28
Redox Pharmaceutical Corporation, H2 2012 29
Sirnaomics, Inc., H2 2012 30
SIFI Pharma, H2 2012 31
Altacor Ltd., H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 39
Eye Infections Therapeutics – Drug Profile Updates 64
Eye Infections Therapeutics – Discontinued Products 70
Eye Infections Therapeutics – Dormant Products 71
Eye Infections Therapeutics – Dormant Products (Contd..1) 72

List of Figures
Number of Products under Development for Eye Infections, H2 2012 9
Products under Development for Eye Infections – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

- Bausch & Lomb Incorporated
- Lux Biosciences, Inc.
- InSite Vision Incorporated
- NanoViricides, Inc.
- Peregrine Pharmaceuticals, Inc.
- RegeneRx Biopharmaceuticals, Inc.
- Foamix Ltd.
- LABORATOIRES THEA
- Redox Pharmaceutical Corporation
- Sirnaomics, Inc.
- SIFI Pharma
- Altacor Ltd.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos